| 17.06 17:41 | Aktien Schweiz etwas leichter - UBS gesucht |
| 17.06 11:08 | dpa-AFX: ANALYSE-FLASH: Goldman belässt Roche auf 'Sell' - Ziel 236 Franken |
| 17.06 11:05 | dpa-AFX: ANALYSE-FLASH: Deutsche Bank belässt Roche auf 'Hold' - Ziel 215 Franken |
| 17.06 07:56 | dpa-AFX: ANALYSE-FLASH: Barclays belässt Roche auf 'Equal Weight' - Ziel 230 Franken |
| 17.06 07:06 | dpa-AFX: ANALYSE-FLASH: JPMorgan belässt Roche auf 'Underweight' - Ziel 210 Franken |
| 16.06 16:11 | dpa-AFX: Roche legt positive Studiendaten für Krebsmittel Columvi vor |
| 15.06 16:00 | Press Release: Roche's Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma |
| 15.06 16:00 | Press Release: Roche's Phase III STARGLO study -2- |
| 15.06 16:00 | dpa-AFX: GNW-Adhoc: Roche's Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma |
| 14.06 17:45 | Aktien Schweiz schlagen sich erneut wacker |
| 13.06 17:47 | Aktien Schweiz halten sich besser als die europäischen Pendants |
| 10.06 17:43 | Aktien Schweiz von schwachem Euro gedrückt |
| 10.06 07:11 | Roche erhält EU-Zulassung für Lungenkrebsmedikament Alecensa |
| 10.06 07:05 | dpa-AFX: GNW-Adhoc: Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization |
| 10.06 07:05 | Press Release: Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization |
| 10.06 07:05 | Press Release: Roche four-in-one molecular test -2- |
| 10.06 07:00 | Press Release: European Commission approves Roche's Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer |
| 10.06 07:00 | Press Release: European Commission approves -2- |
| 10.06 07:00 | dpa-AFX: GNW-Adhoc: European Commission approves Roche's Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer |
| 07.06 16:40 | Press Release: Five-year data for Roche's Evrysdi -2- |
|
|
